HER-2/neu vaccine-primed autologous T-cell infusions for the treatment of advanced stage HER-2/neu expressing cancers

Cancer Immunology, Immunotherapy

Volumn 63, Issue 2, 2014, Pages 101-109

  Disis, Mary L ^a   Dang, Yushe ^a   Coveler, Andrew L ^a   Marzbani, Edmond ^a   Kou, Zhong C ^b   Childs, Jennifer S ^a   Fintak, Patricia ^a   Higgins, Doreen M ^a   Reichow, Jessica ^a   Waisman, James ^c   Salazar, Lupe G ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b BioMed Immunotech Inc   (United States)

^c CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adoptive T cell therapy; Clinical trial; HER2; Phase I; Vaccine

Indexed keywords

ADOPTIVE TRANSFER; ADULT; AGED; CANCER VACCINES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES;

EID: 84894444141     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1489-4     Document Type: Article

References (26)

1. Dudley ME, Wunderlich JR, Yang JC, Sherry RM, Topalian SL, Restifo NP, Royal RE, Kammula U, White DE, Mavroukakis SA et al (2005) Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol 23(10):2346-2357. doi: 10.1200/JCO.2005.00.240
2. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, Kammula U, Robbins PF, Huang J, Citrin DE, Leitman SF et al (2008) Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol 26(32):5233-5239. doi: 10.1200/JCO.2008.16. 5449
3. Tjin EP, Konijnenberg D, Krebbers G, Mallo H, Drijfhout JW, Franken KL, van der Horst CM, Bos JD, Nieweg OE, Kroon BB et al (2011) T-cell immune function in tumor, skin, and peripheral blood of advanced stage melanoma patients: implications for immunotherapy. Clin Cancer Res 17(17):5736-5747. doi: 10.1158/1078-0432.CCR-11-0230
4. Disis ML, Wallace DR, Gooley TA, Dang Y, Slota M, Lu H, Coveler AL, Childs JS, Higgins DM, Fintak PA et al (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27(28):4685-4692. doi: 10.1200/JCO.2008.20.6789
5. Dang Y, Knutson KL, Goodell V, dela Rosa C, Salazar LG, Higgins D, Childs J, Disis ML (2007) Tumor antigen-specific T-cell expansion is greatly facilitated by in vivo priming. Clin Cancer Res 13(6):1883-1891. doi: 10.1158/1078-0432.CCR-06-2083
6. Knutson KL, Disis ML (2004) IL-12 enhances the generation of tumour antigen-specific Th1 CD4 T cells during ex vivo expansion. Clin Exp Immunol 135(2):322-329. doi: 10.1111/j.1365-2249.2004.02360.x
7. Disis ML, Gooley TA, Rinn K, Davis D, Piepkorn M, Cheever MA, Knutson KL, Schiffman K (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20(11):2624-2632. doi: 10.1200/JCO.2002.06.171
8. Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107(4):477-484. doi: 10.1172/JCI11752
9. Kou ZC, Puhr JS, Rojas M, McCormack WT, Goodenow MM, Sleasman JW (2000) T-Cell receptor Vbeta repertoire CDR3 length diversity differs within CD45RA and CD45RO T-cell subsets in healthy and human immunodeficiency virus-infected children. Clin Diagn Lab Immunol 7(6):953-959. doi: 10.1128/CDLI.7.6.953-959. 2000
10. Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA (2010) Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 18(4):843-851. doi: 10.1038/mt.2010.24
11. Okajima M, Wada T, Nishida M, Yokoyama T, Nakayama Y, Hashida Y, Shibata F, Tone Y, Ishizaki A, Shimizu M et al (2009) Analysis of T cell receptor Vbeta diversity in peripheral CD4 and CD8 T lymphocytes in patients with autoimmune thyroid diseases. Clin Exp Immunol 155(2):166-172. doi: 10.1111/j.1365-2249. 2008.03842.x
12. Langerak AW, Groenen PJ, Bruggemann M, Beldjord K, Bellan C, Bonello L, Boone E, Carter GI, Catherwood M, Davi F et al (2012) EuroClonality/BIOMED-2 guidelines for interpretation and reporting of Ig/TCR clonality testing in suspected lymphoproliferations. Leukemia 26(10):2159-2171. doi: 10.1038/leu.2012.246
13. Rapoport AP, Stadtmauer EA, Aqui N, Badros A, Cotte J, Chrisley L, Veloso E, Zheng Z, Westphal S, Mair R et al (2005) Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med 11(11):1230-1237. doi: 10.1038/nm1310
14. Stadtmauer EA, Vogl DT, Luning Prak E, Boyer J, Aqui NA, Rapoport AP, McDonald KR, Hou X, Murphy H, Bhagat R et al (2011) Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial. Blood 117(1):63-71. doi: 10.1182/blood-2010-07- 296822
15. Powell DJ Jr, Dudley ME, Hogan KA, Wunderlich JR, Rosenberg SA (2006) Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. J Immunol 177(9):6527-6539
16. Cesana GC, DeRaffele G, Cohen S, Moroziewicz D, Mitcham J, Stoutenburg J, Cheung K, Hesdorffer C, Kim-Schulze S, Kaufman HL (2006) Characterization of CD4+ CD25+ regulatory T cells in patients treated with high-dose interleukin-2 for metastatic melanoma or renal cell carcinoma. J Clin Oncol 24(7):1169-1177. doi: 10.1200/JCO.2005.03.6830
17. Disis ML, Knutson KL, Schiffman K, Rinn K, McNeel DG (2000) Pre-existent immunity to the HER-2/neu oncogenic protein in patients with HER-2/neu overexpressing breast and ovarian cancer. Breast Cancer Res Treat 62(3):245-252. doi: 10.1023/A:1006438507898
18. Zhu Z, Singh V, Watkins SK, Bronte V, Shoe JL, Feigenbaum L, Hurwitz AA (2013) High-avidity T cells are preferentially tolerized in the tumor microenvironment. Cancer Res 73(2):595-604. doi: 10.1158/0008-5472.CAN-12-1123
19. Brentville VA, Metheringham RL, Gunn B, Durrant LG (2012) High avidity cytotoxic T lymphocytes can be selected into the memory pool but they are exquisitely sensitive to functional impairment. PLoS ONE 7(7):e41112. doi: 10.1371/journal.pone.0041112
20. Comoli P, Pedrazzoli P, Maccario R, Basso S, Carminati O, Labirio M, Schiavo R, Secondino S, Frasson C, Perotti C et al (2005) Cell therapy of stage IV nasopharyngeal carcinoma with autologous Epstein-Barr virus-targeted cytotoxic T lymphocytes. J Clin Oncol 23(35):8942-8949. doi: 10.1200/JCO.2005.02.6195
21. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C et al (2011) A human memory T cell subset with stem cell-like properties. Nat Med 17(10):1290-1297. doi: 10.1038/nm.2446
22. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, Citrin DE, Restifo NP, Robbins PF, Wunderlich JR et al (2011) Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin Cancer Res 17(13):4550-4557. doi: 10.1158/1078-0432.CCR-11-0116
23. Pilch H, Hohn H, Neukirch C, Freitag K, Knapstein PG, Tanner B, Maeurer MJ (2002) Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor. Clin Diagn Lab Immunol 9(2):267-278. doi: 10.1128/CDLI.9.2.267-278.2002
24. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154(8):3961-3968
25. Yao X, Ahmadzadeh M, Lu YC, Liewehr DJ, Dudley ME, Liu F, Schrump DS, Steinberg SM, Rosenberg SA, Robbins PF (2012) Levels of peripheral CD4(+)FoxP3(+) regulatory T cells are negatively associated with clinical response to adoptive immunotherapy of human cancer. Blood 119(24):5688-5696. doi: 10.1182/blood-2011-10-386482
26. Fridman WH, Pages F, Sautes-Fridman C, Galon J (2012) The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 12(4):298-306. doi: 10.1038/nrc3245